GAMMA Investing’s KalVista Pharmaceuticals KALV Stock Holding History

GAMMA Investing’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-639	Closed	-$12.9K	–	4194
2026 Q1	$12.9K	Buy	639 +414	+184%	+$6.67K	﹤0.01%	2936
2025 Q4	$3.63K	Sell	225 -194	-46%	-$2.57K	﹤0.01%	3411
2025 Q3	$5.1K	Sell	419 -22	-5%	-$304	﹤0.01%	3171
2025 Q2	$4.99K	Buy	441 +57	+15%	+$697	﹤0.01%	3119
2025 Q1	$4.43K	Sell	384 -280	-42%	-$2.86K	﹤0.01%	3133
2024 Q4	$5.62K	Buy	664 +605	+1,025%	+$6.27K	﹤0.01%	2867
2024 Q3	$683	Buy	+59	New	+$742	﹤0.01%	3345
2024 Q2	–	Sell	-16	Closed	-$190	–	3487
2024 Q1	$190	Hold	16	–	–	﹤0.01%	3230
2023 Q4	$252	Buy	+16	New	+$146	﹤0.01%	3105

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's KALV Position: Q2 2026 in Review

GAMMA Investing sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 639 shares — an estimated $12.9K sold.

GAMMA Investing first reported a position in KALV in Q4 2023 and held it in 9 quarters. The position peaked at $12.9K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

GAMMA Investing reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
GAMMA Investing sold 639 KalVista Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
GAMMA Investing first reported a position in KalVista Pharmaceuticals in Q4 2023 and held it in 9 quarters.
GAMMA Investing's KalVista Pharmaceuticals position peaked at $12.9K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.